Novartis, a leading pharmaceutical company, has agreed to purchase a promising new drug called SNV4818 from a company called Synnovation Therapeutics. This drug works by targeting a specific protein involved in some breast cancers. As part of the deal, Novartis will pay $2 billion upfront and could pay up to an additional $1 billion if certain milestones are met. The purchase includes Pikavation Therapeutics, the company that owns SNV4818, and its related programs. The agreement is expected to be finalized in the first half of 2026, pending regulatory approvals.
SNV4818 is taken as a pill and is currently being tested in early-stage clinical trials for breast cancer and other advanced solid tumors. The drug is designed to treat a specific type of breast cancer called hormone receptor-positive (HR+) / human epidermal growth factor receptor 2 (HER2)- breast cancer, which is one of the most common forms of the disease. It may also be useful for other related cancers.
The drug works by precisely targeting cancer cells with mutations in the PI3Kα gene, a change found in many breast cancers. Preclinical studies have shown that it effectively blocks the activity of this gene mutation. If successful, SNV4818 could offer a new treatment option that is better tolerated and provides longer-lasting benefits for patients, compared to current therapies.
Shreeram Aradhye, the head of Novartis’s development team, explained, ‘Mutations in the PI3Kα gene play a significant role in HR+/HER2- breast cancer, but existing treatments can be challenging to tolerate. SNV4818 uses a new approach that more accurately targets cancer cells while sparing healthy cells, which could lead to fewer side effects and better outcomes for patients.’
In a separate development, Novartis also recently received approval from the U.S. Food and Drug Administration (FDA) for Cosentyx (secukinumab), a drug already used for other conditions, to treat pediatric patients aged 12 and older with a chronic skin condition called hidradenitis suppurativa.